Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Medical System Holdings ( (HK:0867) ) just unveiled an update.
China Medical System Holdings Limited has entered into exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for two innovative biologic products: Vecantoxatug Injection, aimed at passive immunization against tetanus, and Silevimig Injection, targeting rabies virus exposure. These agreements grant the company commercialization rights in mainland China and licensing rights across the Asia-Pacific, Middle East, and North Africa regions. The collaboration enhances the company’s portfolio in passive immunization, potentially offering advanced therapeutic options with improved safety and accessibility, thus strengthening its market position in the biopharmaceutical sector.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$15.60 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutic biological products. The company collaborates with partners to bring advanced medical solutions to the market, with a particular emphasis on passive immunization therapies.
YTD Price Performance: 104.66%
Average Trading Volume: 11,001,183
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.64B
For a thorough assessment of 0867 stock, go to TipRanks’ Stock Analysis page.